Rezafungin: ทางเลือกใหม่สำหรับรักษาการติดเชื้อแคนดิดาในกระแสเลือดและการติดเชื้อแคนดิดาแบบรุกราน
Year: 2024
Type: review
Abstract: Rezafungin is a second-generation echinocandin, following in the footsteps of anidulafungin, micafungin, and caspofungin. It works by inhibiting 1,3-β-D-glucan synthase, an enzyme involved in the synthesis of fungal cell walls. Administered as a once-weekly intravenous injection, it received approval from the United States Food and Drug Administration on March 22, 2017. Rezafungin is indicated for the treatment of candidemia and invasive candidiasis in patients aged 18 years and older who have limited or no alternative treatment options. Additionally, Rezafungin has been developed for the prevention of fungal infections in patients undergoing bloodstream and bone marrow transplants. Systematic reviews have demonstrated that its long half-life allows for weekly administration. Rezafungin is also safer to use than first-generation echinocandins, as it has lower hepatotoxicity.
Author: Sawekkulchol, Suwitcha
Institution: King Chulalongkorn Memorial Hospital
Language: Thai
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7219543888
